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Abstract
Background: Kaposi’s sarcoma (KS) is a vascular neoplasm characterized by the dysregulated expression of angiogenic and
inflammatory cytokines. The driving force of the KS lesion, the KSHV-infected spindle cell, secretes elevated levels of vascular
endothelial growth factor (VEGF), essential for KS development. However, the origin of VEGF in this tumor remains unclear.
Methodology/Principal Findings: Here we report that the KSHV G protein-coupled receptor (vGPCR) upregulates VEGF in
KS through an intricate paracrine mechanism. The cytokines secreted by the few vGPCR-expressing tumor cells activate in
neighboring cells multiple pathways (including AKT, ERK, p38 and IKKb) that, in turn, converge on TSC1/2, promoting mTOR
activation, HIF upregulation, and VEGF secretion. Conditioned media from vGPCR-expressing cells lead to an mTOR-
dependent increase in HIF-1a and HIF-2a protein levels and VEGF upregulation. In a mouse allograft model for KS, specific
inhibition of the paracrine activation of mTOR in non-vGPCR-expressing cells was sufficient to inhibit HIF upregulation in
these cells, and abolished the ability of the vGPCR-expressing cells to promote tumor formation in vivo. Similarly,
pharmacologic inhibition of HIF in this model blocked VEGF secretion and also lead to tumor regression.
Conclusions/Significance: Our findings provide a compelling explanation for how the few tumor cells expressing vGPCR
can contribute to the dramatic amplification of VEGF secretion in KS, and further provide a molecular mechanism for how
cytokine dysregulation in KS fuels angiogenesis and tumor development. These data further suggest that activation of HIF
by vGPCR may be a vulnerable target for the treatment of patients with KS.
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Introduction
Kaposi’s sarcoma (KS) is a multifocal vascular neoplasm
invariably associated with infection with the KS-associated human
herpesvirus (KSHV/HHV8), which is characterized by cytokine
dysregulation [1]. The driving force of the KS lesion is the KSHV-
infected spindle-shaped tumor (spindle) cell, thought to have a
vascular endothelial or endothelial precursor origin. The promo-
tion of the angiogenic phenotype in these lesions is supposed to be
mediated by elevated levels of pro-inflammatory and pro-
angiogenic secretions (cytokines, chemokines and growth factors)
from the KS spindle cells [1]. Indeed, KS is often thought to result
from reactive endothelial hyperproliferation induced by the
chronic release of these molecules and has served as a model for
tumor- and inflammation-induced angiogenesis [1,2].
Among the angiogenic factors elaborated by the KS spindle
cells, VEGF is unique for its profound impact on KS pathogenesis.
VEGF is expressed at elevated levels by KSHV-infected
endothelial cells in vitro, and by KS spindle cells in vivo; a strict
requirement for VEGF has also been demonstrated for KS spindle
cells grown in vitro [3,4,5,6]. These observations are suggestive of
an autocrine mechanism for this angiogenic factor in the growth of
this vascular tumor. Indeed, like VEGF, its cognate receptor,
VEGFR2 (KDR), is also upregulated in AIDS-KS primary lesions
as well as in AIDS-KS spindle cell cultures [4,7,8]. However,
reasonable disagreement remains as to the precise molecular
mechanism whereby KSHV promotes VEGF secretion.
Of interest, KSHV ORF74 encodes for a viral G protein-coupled
receptor (vGPCR) with close homology to the mammalian CXCR1
and CXCR2 and ligand-independent (constitutive) activity [9,10].
When expressed upon endothelial-specific retroviral infection or as a
transgene, vGPCR is sufficient to recapitulate KS-like lesions in mice
[11,12,13]. Indeed, emerging data suggest that vGPCR may play a
role in KS initiation, progression and maintenance [12,14,15].
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19103vGPCR has proven to be a powerful oncogene and a potent
angiogenic activator [1]. Expression of vGPCR in endothelial cells
activates intracellular pathways that induce cell survival and
transformation. In addition, vGPCR-expressing cells elaborate
pro-angiogenic factors that are thought to promote the recruit-
ment and transformation of neighboring endothelial cells [16].
Both VEGF and KDR have been previously reported to be
upregulated by cells expressing vGPCR [7,8,17,18]. However, the
limited expression of this viral oncogene in only a few tumor cells
in both transgenic KS mouse models and human KS tissues raises
the question as to the relative contribution of vGPCR to VEGF
secretion, suggesting that the relationship between vGPCR and
VEGF is not clearly established. Here we set out to further
characterize the contribution of vGPCR to the upregulation of
VEGF secretion in KS.
Results
vGPCR activates VEGF expression through a paracrine
mechanism dependent on mTOR
The KSHV-encoded vGPCR causes angioproliferative lesions
remarkably similar to human KS, when expressed upon
endothelial-specific retroviral infection in immunocompetent
animals (Fig. 1A–B) [12]. Interestingly, immunohistochemical
staining of these vGPCR tumors using a specific vGPCR antibody
reveals the presence of this viral protein in only a small percentage
of tumor cells, similar to the expression pattern of vGPCR in
human KS, suggestive of a paracrine contribution of vGPCR to
Kaposi’s sarcomagenesis (Fig. 1B) [12,13]. In this regard, vGPCR
has been implicated in the induction of the expression of VEGF, a
key angiogenic factor highly upregulated in KS [17,18]. However,
staining of vGPCR tumors – and human KS – with a specific
antibody against VEGF reveals a robust expression of this factor in
most tumor cells (Fig. 1B), indicating that vGPCR may also
upregulate VEGF in neighboring cells through an indirect
mechanism. To explore this possibility, we used an inducible
(Tet-on) expression system for vGPCR in immortalized human
microdermal endothelial cells (HMEC1). Using this system, we
confirmed that induction of vGPCR expression in endothelial cells
leads to the potent upregulation of VEGF, as previously reported
(Fig. 1C) [17,18]. Moreover, we observed that exposure of
HMEC1 to media conditioned by these vGPCR-expressing cells
(vGPCR CM) is similarly able to promote VEGF expression
(Fig. 1C).
We therefore set out to determine the mechanism whereby
vGPCR angiogenic factors can induce VEGF upregulation. In this
regard, we have previously reported that vGPCR paracrine
secretions activates TSC/mTOR, a signaling route that has been
shown to regulate the expression of VEGF [19,20]. We thus
treated HMEC1s with supernatants derived from vGPCR-
expressing cells (vGPCR CM) or control cells (Control CM), in
the absence or the presence of the mTOR inhibitor, Rapamycin.
Figure 1D shows that exposure of endothelial cells to vGPCR
secreted factors leads to the upregulation of the transcription and
translation of VEGF in a Rapamycin-sensitive manner.
To further evaluate the contribution of the vGPCR-induced
paracrine activation of mTOR to VEGF upregulation in vivo,w e
used an allograft model in which (SV-40) immortalized murine
endothelial cells (SVECs) expressing vGPCR (EC-vGPCR) are
mixed with SVECs co-expressing two non-tumorigenic KSHV
latent genes, vCyclin and vFLIP (EC-vCYC/vFLIP), in a (1:10)
ratio that approximates the proportion of expressing cells in
human KS (Fig. 1E) [15]. Cells expressing vCYC and vFLIP do
not show VEGF upregulation in vitro nor are they tumorigenic in
vivo (data not shown; [15]). However, these cells (EC-vCYC/
vFLIP) are able to induce allografts in nude mice when co-injected
with vGPCR-expressing cells (EC-vGPCR) (Fig. 1E). Immunohis-
tochemical staining of these lesions also shows upregulation of
VEGF in most tumor cells (Fig. 1E). Interestingly, when these
mixed-cell allografts are treated with Rapamycin, which is able to
block vGPCR tumorigenesis [19], a reduction in VEGF expression
in treated tumors is observed. Collectively, these results suggest
that the paracrine upregulation of VEGF by vGPCR requires the
activation of the mTOR signaling cascade in vitro and in vivo.
vGPCR paracrine secretions activate mTOR through
multiple signaling pathways
Diverse extracellular stimuli influence mTOR activity through
posttranslational modification of TSC1/TSC2 [20]. Indeed,
numerous kinases are able to phosphorylate TSC1 or TSC2,
integrating extracellular signals and tumorigenesis through the
control of TSC1/TSC2/mTOR [21]. Among these kinases,
AKT, ERK, and p38/MK2 have been shown to phosphorylate
TSC2 in specific sites, including Thr
1462, Ser
664 and Ser
1254,
respectively [22,23,24,25,26]. Conversely, IKKb induces mTOR
activation by phosphorylating TSC1 in Ser
487 and Ser
511 [27].
We have previously shown that induction of AKT activity by
vGPCR promotes mTOR activation in neighboring cells [19].
However, the contribution of other kinases upstream of TSC/
mTOR to vGPCR oncogenesis remains unclear. We thus treated
HMEC1 with media conditioned by control or vGPCR-expressing
cells and assessed the activation of TSC kinases by these
supernatants. In addition to AKT, we found that ERK, p38 and
IKKb were also activated by vGPCR paracrine secretions
(Fig. 2A). Activation of these kinases correlated with the
phosphorylation of TSC2 in Thr
1462, Ser
664 and Ser
1254, and
phosphorylation of TSC1 in Ser
511, respectively, and the
upregulation of mTOR activity, assessed by S6K phosphorylation
(Fig. 2A). We also evaluated the activation of these TSC1/2
kinases by individual GPCR angiogenic factors [14,28]. Figure S1
shows that all the cytokines tested were able to induce
phosphorylation of TSC1 and/or TSC2. Interestingly, IL-1b,
IL-10, TNFa and VEGF are each able to promote phosphory-
lation of TSC1/2 on at least three separate sites (Fig. S1).
Collectively, these results suggest that the secreted factors
elaborated by vGPCR-expressing cells act together to upregulate
multiple intracellular signaling pathways that converge on TSC/
mTOR.
To determine the relative contribution of these TSC kinases to
the paracrine mTOR activation by vGPCR, we used specific
inhibitors of PI3K/AKT, MEK/ERK, p38 or IKKb. Surprising-
ly, we observed that either pharmacological inhibition of AKT-
mediated phosphorylation of TSC2 or IKKb-mediated phosphor-
ylation of TSC1 lead to a complete inhibition of mTOR,
measured by S6K phosphorylation (Fig. 2A). Conversely,
pharmacological inhibition of either ERK or p38 leads to only
partial inhibition of ERK-mediated or p38-mediated S6K
phosphorylation, respectively. We then used siRNA to specifically
knock-down expression of AKT, ERK1 and 2, p38, or IKKb.
Knock-down of these kinases was only sufficient to partially inhibit
mTOR (Fig. 2B). Collectively, these results suggest that there is a
redundancy in the pathways leading to the phosphorylation of
TSC1 and 2 and the activation of mTOR by the paracrine
secretions of vGPCR-expressing cells.
We then stained murine vGPCR tumors and human KS tissues
with specific antibodies against the phosphorylated (activated)
forms of AKT, ERK, p38 or IKKb or against the corresponding
TSC2/TSC1 phosphorylated form, induced by each kinase
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PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e19103Figure 1. vGPCR activates VEGF expression through an mTOR-dependent paracrine mechanism. (A) KS-like lesion developed upon
retroviral transduction of vGPCR in TIE2-tva mice (vGPCR tumor), as described in Materials and Methods. (B) H&E and immunohistochemical stainings
of vGPCR tumor and human KS, using antibodies against vGPCR, VEGF or an isotype-matched control antibody. (C) Upregulation of VEGF in HMEC1s
transfected with Tet REV TA and pBIG AU5 vGPCR and treated with doxycycline (vGPCR), respect to untreated cells (Control). VEGF upregulation in
HMEC1 exposed for 2 h or 6 h to supernatants collected from vGPCR-expressing cells (vGPCR CM). (D) Supernatants from vGPCR-expressing cells
(vGPCR CM) or control cells (Control CM) were used to treat HMEC1 in the presence or absence of Rapamycin (50 nM). RT-PCR and Western blot
analysis were used to determine levels of VEGF mRNA and protein, respectively. (E) EC-vGPCR (10%) were mixed with EC- vCYC/vFLIP (90%), and
injected into athymic nu/nu mice for allograft formation. Tumor weight curves, and immunohistochemical detection in tumor tissue of (AU5-tagged)
vGPCR-expressing cells, phosphorylated ribosomal S6 protein or VEGF, upon treatment with (10 mg/kg) Rapamycin of vehicle (Control), are shown.
doi:10.1371/journal.pone.0019103.g001
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phosphorylation of these four kinases and the corresponding
targeted aminoacids in TSC2 or TSC1, in both vGPCR tumors
and human KS (Fig. 2C). These findings suggest a role for these
kinases upstream of TSC/mTOR in vGPCR tumorigenesis and
Kaposi’s sarcomagenesis in vivo.
Paracrine activation of TSC/mTOR by vGPCR angiogenic
factors results in the upregulation of HIF-1a/2a
TSC/mTOR has been shown to regulate Hypoxia Inducible
Factor (HIF), a family of transcription factors containing an
inducible a subunit and a constitutive b subunit [20,29]. HIF
promotes neovascularization and vascular remodeling by control-
ling the expression of key angiogenic proteins, including VEGF
[30]. Since vGPCR angiogenic factors activate TSC/mTOR
through a variety of intracellular routes, we next investigated
whether this activation could lead to the upregulation of VEGF
through a HIF-dependent mechanism. To this end, we treated
HMEC1 with media conditioned by vGPCR-expressing cells or
control cells, in the absence or presence of Rapamycin, and
examined the levels of HIF-1a and HIF-2a mRNA and protein.
Interestingly, we found that vGPCR angiogenic factors induced an
upregulation of HIF-1a mRNA (3-fold) and HIF-2a mRNA (18-
fold); both were blocked by the mTOR inhibitor (Fig. 3A).
Upregulation of HIF-1a, HIF-2a and VEGF protein levels by
vGPCR secretions was also blocked by Rapamycin (Fig. 3A).
Furthermore, the increase in VEGF transcription and translation
by vGPCR supernatants was blocked by the expression of a
specific siRNA of HIF-1b (Fig. 3B). When we investigated the
levels of HIF-1a and HIF-2a proteins in vGPCR murine tumors
and KS biopsy specimens by immunohistochemical analysis, we
found that both vGPCR murine tumors and human KS showed a
remarkable overexpression of these transcription factors, com-
pared to normal skin (results not shown) (Fig. 3C). Collectively,
these results suggest that vGPCR may induce paracrine upregula-
tion of VEGF through an mTOR/HIF-dependent mechanism.
Figure 2. vGPCR secretions regulate TSC/mTOR through multiple signaling pathways in vitro and in vivo. (A) HMEC1s were pretreated
with vehicle or inhibitors of the AKT, ERK, p38 or IKKb pathways, LY294002 (50 mM), U0126 (50 mM), SB203580 (50 mM) or BAY11-7082 (40 mM). Cells
were then exposed to media conditioned by control cells (Control CM) or vGPCR-expressing cells (vGPCR CM). Phosphorylation levels of the
corresponding kinase (AKT, ERK1/2, p38 or IKKb), TSC2/1 targeted phosphorylation site (P-TSC2
T1462, P-TSC2
S664, P-TSC2
S1254 or P-TSC1
S511), and S6K
are shown. (B) HMEC1s were transfected with Scrambled siRNA or siRNA for AKT, ERK (ERK1 and 2), p38 or IKKb. Cells were then exposed to media
conditioned by control or vGPCR-expressing cells. Levels of the corresponding kinase (AKT, ERK1/2, p38 or IKKb) and S6K are shown. (C)
Immunohistochemical staining of vGPCR tumors and human KS with antibodies against P-AKT, P-ERK, P-p38 or P-IKKb, and the corresponding TSC2/1
targeted phosphorylation site, P-TSC2
T1462, P-TSC2
S664, P-TSC2
S1254 or P-TSC1
S511.
doi:10.1371/journal.pone.0019103.g002
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upregulation in vGPCR sarcomagenesis in vivo
vGPCR activates mTOR through both direct and indirect
mechanisms and both may thus contribute to endothelial cell
transformation and angiogenic dysregulation in KS. To assess the
relative contribution of vGPCR direct versus paracrine activation
of TSC/mTOR/HIF to vGPCR oncogenesis, we generated cell
lines co-expressing vGPCR or vCYC/vFLIP along with a
Rapamycin-Resistant mTOR mutant (RR-mTOR) that bears a
Ser
2035RIle (SI) substitution in the FKBP12-Rapamycin-binding
domain (EC-vGPCR/RR-mTOR or EC-vCYC/vFLIP/RR-
mTOR) [19]. Expression of RR-mTOR strongly protected
vGPCR- and vCYC/vFLIP-expressing cells from the ability of
Rapamycin to inhibit mTOR activation in vitro (data not shown).
We then established mixed-cell allografts injecting athymic nu/nu
mice with EC-vGPCR (10%) + EC-vCYC/vFLIP (90%) cells, EC-
vGPCR/RR-mTOR (10%) + EC- vCYC/vFLIP (90%) cells or
EC-vGPCR (10%) + EC- vCYC/vFLIP/RR-mTOR (90%) cells
and treated established tumors with Rapamycin or vehicle (Fig. 4).
Similar to EC-vGPCR+EC-vCYC/vFLIP tumors, growth of
allografts formed upon injection with EC-vGPCR/RR-mTOR +
EC-vCYC/vFLIP was strongly inhibited by treatment with
Rapamycin, suggesting that protection from the inhibition of
direct mTOR activation within vGPCR-expressing cells was not
sufficient to render these tumors sensitive to the drug. Conversely,
allografts derived from the injection of EC-vGPCR (10%) + EC-
vCYC/vFLIP/RR-mTOR (90%) cells continued growing even
upon treatment with Rapamycin, suggesting that the sensitivity to
the drug of these allografts is due to the inhibition of the paracrine
activation of mTOR in neighboring cells by the angiogenic factors
elaborated by vGPCR-expressing cells (Fig. 4). Of interest, tissue
staining with a phospho-S6 ribosomal protein specific antibody
confirmed the inhibition of mTOR activity in most cells of EC-
vGPCR (10%) + EC-vCYC/vFLIP (90%) as well as EC-vGPCR/
RR-mTOR (10%) + EC- vCYC/vFLIP (90%) tumors, but not
EC-vGPCR (10%) + EC- vCYC/vFLIP/RR-mTOR (90%)
Figure 3. Upregulation of HIF-1a/2a by vGPCR paracrine secretions. (A) HMEC1s were exposed to media conditioned by control (Control CM)
or vGPCR-expressing cells (vGPCR CM), in the presence of vehicle or Rapamycin (50 mM). mRNA levels of HIF-1a and HIF-2a and protein levels of HIF-
1a, HIF-2a and VEGF are shown. (B) HMEC1s were transfected with increasing doses (20, 40 and 80 nM) of HIF-1b siRNA or Scrambled siRNA. Cells
were then exposed to media conditioned by vGPCR-expressing cells. VEGF mRNA levels are shown. (C) Immunohistochemical analysis of HIF-1a and
HIF-2a, and staining using an isotype-matched control antibody, in vGPCR tumor and human KS.
doi:10.1371/journal.pone.0019103.g003
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levels were reduced in treated tumors but remained elevated in
most tumor cells of EC-vGPCR (10%) + EC- vCYC/vFLIP/RR-
mTOR (90%) allografts even after treatment with Rapamycin
(Fig. 5). Collectively, these findings support an essential role of
vGPCR paracrine secretions in the mTOR-driven promotion of
HIF stabilization and VEGF secretion, and in vGPCR tumori-
genesis.
Inhibition of HIF blocks vGPCR tumorigenesis in vivo
Of interest, several drugs have been recently described that
target HIF expression or activity; these drugs have demonstrated
anti-angiogenic and anti-cancer effects in vivo [30]. The
identification of HIF as a key factor in vGPCR angiogenic
amplification prompted us to explore inhibition of HIF as a
potential therapeutic approach for KS treatment. We therefore
established tumor allografts by injecting mixed-cell populations of
EC-vGPCR and EC-vCYC/vFLIP cells in athymic nu/nu mice
(Fig. 6). Animals were then treated with either (2 mg/kg)
Digoxin, a cardiac glycoside that has been shown to inhibit
HIF-1a synthesis and block tumor formation, or vehicle (Control)
(Fig. 6) [31]. Drug toxicity, as assessed by weight loss, was
minimal in the treated group (reduction ,5%) during the
treatment period (results not shown). Inhibition of tumor growth
by the treatment with Digoxin was sustained for the duration of
the experiment. At the end of the study, we observed that the
average estimated weight of vehicle-treated tumors was 702 mg (a
4.8 fold increase) vs. an average estimated weight of 234 mg (a
1.7 fold increase) of Digoxin-treated tumors (Fig. 6). Immuno-
histochemical analysis of these lesions demonstrated a dramatic
reduction in the levels of HIF as well as VEGF in the Digoxin-
treated animals compared to control mice (Fig. 6). Taken
together, our data provide the basis for the early assessment of
HIF inhibitors as an anti-KS therapy.
Discussion
KS is an angioproliferative tumor characterized by the presence
of angiogenic and inflammatory mediators [1]. The observation
that KS tumors tend to localize to sites of inflammation suggests
that these lesions thrive in a cytokine-rich environment [1].
Indeed, KS spindle cells do not appear to be truly transformed;
rather, the KS spindle cell elaborates a variety of cytokines,
chemokines and growth factors that are essential for their growth
and survival. Indeed, isolated KS spindle cells remain strictly
dependent on cytokines and growth factors to proliferate in vitro
and are not tumorigenic when tested in animal models. Among the
numerous angiogenic mediators on which the KS spindle cell is
dependent, VEGF has been shown to be essential for KS spindle
cell survival in vitro and KS pathogenesis in vivo.
We previously reported a mechanism whereby the KSHV
vGPCR promotes the upregulation of VEGF transcription in
Figure 4. Paracrine activation of mTOR is required for vGPCR sarcomagenesis in vivo. Tumor allografts were generated upon injection of
athymic nu/nu mice with EC-vGPCR (10%) + EC-vCYC/vFLIP (90%) cells, EC-vGPCR/RR-mTOR (10%) + EC-vCYC/vFLIP (90%) cells or EC-vGPCR (10%) +
EC-vCYC/vFLIP/RR-mTOR (90%) cells. Lesions were then treated with (10 mg/kg) Rapamycin or vehicle. Curves of tumor growth and
immunohistochemical staining of tumor tissue with anti-AU1 or anti-AU5 antibodies, revealing expression of RR-mTOR or vGPCR, respectively, are
shown.
doi:10.1371/journal.pone.0019103.g004
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upregulates VEGF through a complex indirect (paracrine)
mechanism. Upregulation of VEGF in neighboring (non-
vGPCR-expressing) tumor cells results in a dramatic amplification
of the angiogenic signal promoted by vGPCR and helps provide
an explanation for how this unusual viral oncogene can play a role
in KS despite the observation that its expression is restricted to
only a few tumor cells. vGPCR angiogenic amplification involves
the secretion of angiogenic and inflammatory cytokines by
vGPCR-expressing cells which then activate in neighboring cells
Figure 5. Paracrine activation of mTOR is required for HIF upregulation in vGPCR sarcomagenesis. Immunohistochemical staining with
specific antibodies against phospho-S6 ribosomal protein, HIF-1a and HIF-2a of the allografts generated upon injection of EC-vGPCR (10%) + EC-
vCYC/vFLIP (90%), EC-vGPCR/RR-mTOR (10%) + EC-vCYC/vFLIP (90%) or EC-vGPCR (10%) + EC-vCYC/vFLIP/RR-mTOR (90%), treated with vehicle or
(10 mg/kg) Rapamycin.
doi:10.1371/journal.pone.0019103.g005
Figure 6. Inhibition of HIF blocks vGPCR tumorigenesis in vivo. Tumor allografts were generated upon injection of athymic nu/nu mice with
EC-vGPCR (10%) + EC-vCYC/vFLIP (90%) cells. Lesions were treated with (2 mg/kg) Digoxin or vehicle. Tumor growth curves and
immunohistochemical staining of tumor tissue with anti-AU5 (revealing vGPCR-expresing cells), anti-HIF-2a or anti-VEGF antibody, are shown.
doi:10.1371/journal.pone.0019103.g006
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and 2, resulting in de-repression of mTOR and the promotion of
HIF upregulation and VEGF transcription and secretion (Fig. 7).
TSC kinases activated by vGPCR paracrine secretions include
AKT, ERK, p38 and IKKb, inducing phosphorylation of TSC2/
1 at specific regulatory sites [22,23,24,25,26,27]. Although
pharmacological inhibition of AKT-mediated phosphorylation of
TSC2 or IKKb-mediated phosphorylation of TSC1 lead to a
complete inhibition of mTOR activity, siRNA knock down
expression of AKT, ERK1 and 2, p38, or IKKb was only
sufficient to partially inhibit S6K phosphorylation. This suggests
either that the PI3K/AKT inhibitor, LY294002, and the IKKb
inhibitor, BAY 11-7082, have non-specific inhibitory effects, or
that the RNAi knockdown of AKT and IKKb were less efficient
than their pharmacological inhibition. Although we suspect the
former to be true, regulation of mTOR through these pathways
has proven to be quite complex and the answer may not prove to
be straightforward. Nonetheless, our results collectively suggest
that there is a redundancy in these pathways and in the
phosphorylation sites for inhibiting TSC activity and further
provide insight into the complexity of mTOR regulation by
different exogenous stimuli.
A number of vGPCR factors promote the phosphorylation of
TSC1/2 through several of these signaling pathways. Surprisingly,
we demonstrate here that phosphorylation of TSC1 in Ser
511 by
IKKb is activated by most of the cytokines tested (Fig. S1),
suggesting that regulation of mTOR by IKKb may be quite
promiscuous. Moreover, as IKKb activation leads to the activation
of NFkB, this, in turn, may promote a positive feedback loop,
further enhancing cytokine – and therefore VEGF – secretion in
KS. Of note, paracrine secretions from vGPCR-expressing cells
promote a gene expression profile with an NFkB signature in
endothelial cells [32]. In light of our results here, this suggests that
the NFkB signature may be mediated by the specific secreted
cytokines that promote the activation of IKKb. Ultimately, further
investigation into the relative contribution of each of these
cytokines to the angiogenic phenotype in KS as well as in other
tumors may be warranted.
Several additional KSHV genes have also been shown to
upregulate cytokine levels. These viral proteins, including
vFLIP, kaposin A, kaposin B, K1 and K15, undoubtedly
contribute to the inflammatory milieu observed in KS
[33,34,35,36,37,38]. As KSHV infection itself has been
demonstrated to induce cytokine release [1], the relative
contribution of each of the KSHV genes to cytokine dysregu-
lation and the angiogenic phenotype in KS remains to be
determined. Moreover, various inflammatory cytokines, includ-
ing IL-1, TNF-a and interferon-c (IFN—c), are increased upon
HIV infection, an important cofactor in KS development [39].
Collectively, these findings suggest that cytokine dysregulation
and TSC/mTOR/HIF/VEGF activation may be a general
mechanism linking KS co-factors, inflammation, and dysregu-
lated angiogenesis in KS.
The mTOR signaling pathway is a key modulator of protein
translation and has previously been identified as a positive
regulator of HIF and HIF-dependent responses [20,30].
Oncogenes activating this pathway have been implicated in
tumor-induced angiogenesis in other tumors. vGPCR promo-
tion of the paracrine activation of mTOR may play a similar
role in the regulation of HIF in KS. Indeed, upregulation of
HIF activity has been observed upon KSHV infection of
endothelial cells in culture and HIF stabilization has been
previously reported in AIDS-KS lesions [40,41]. Of note, other
KSHV genes (e.g. LANA-1 and IRF-3) have also been
suggested to play a role in upregulating HIF activity
[42,43,44]. Given the central role of HIF in VEGF regulation,
and the importance of VEGF in KS, it is certainly reasonable to
argue that KSHV may encode a redundancy of mechanisms to
Figure 7. vGPCR cytokines activate VEGF secretion through diverse signaling cascades converging in TSC/mTOR/HIF. Schematic
showing the different signaling pathways by which vGPCR cytokines, chemokines and growth factors converge in the phosphorylation of TSC1/2, the
activation of mTOR and the upregulation of HIF levels, leading to VEGF secretion.
doi:10.1371/journal.pone.0019103.g007
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in growing KS tumors.
Here, we show that pharmacological inhibition of HIF
upregulation by vGPCR is sufficient to inhibit vGPCR oncogen-
esis. As the master regulator of the hypoxic vascular response, it
should not be surprising that HIF plays a central role in Kaposi’s
sarcomagenesis. HIF drives transcriptional activation of hundreds
of genes involved in vascular reactivity, angiogenesis, arteriogen-
esis, and the recruitment of endothelial precursor cells, all key steps
toward the development of KS [45]. Indeed, it is tempting to
speculate that recent publications describing KS regression in
patients with iatrogenic KS following a switch in their immuno-
suppressive treatment to the mTOR inhibitor, Sirolimus, may – in
part – be due to its effect on decreasing HIF activation [46,47].
Collectively, our data ultimately provide the basis for the early
assessment of drugs inhibiting HIF in those patients with
cutaneous and/or systemic KS.
Materials and Methods
Expression plasmids and reagents
The expression plasmid encoding for the rapamycin-resistant
mTOR mutant (RR-mTOR) that bears a Ser
2035RIle (SI)
substitution in the FKBP12-rapamycin-binding domain has been
described elsewhere [19]. A tetracycline inducible system (Tet-on)
was used for vGPCR expression. pCEFL Tet REV TA and pBIG
AU5 vGPCR were kindly provided by Dr. Silvio Gutkind
(NIDCR, NIH). GRO-a was obtained from R&D Systems; IL-8,
VEGF, PDGF, IL-1b, IL-10, IL-6, TNFa, IP-10 and SDF-1a
were obtained from Peprotech. Rapamycin, LY294002, U0126,
SB203580 and BAY 117082 were purchased from Calbiochem
and Digoxin from Sigma. All siRNA oligos were obtained from
Qiagen.
Cell lines, transfections and supernatant collection
Immortalized human dermal microvascular endothelial cells
(HMEC1) were obtained from the Centers of Disease Control
(Atlanta, GA) and grown in Gibco MCDB 131 medium
(Invitrogen), supplemented with 10% FBS, 10 mM/l L-Gluta-
mine, 10 ng/ml epidermal growth factor, 1 mg/ml hydrocortisone
and 1% antibiotic antimycotic. (SV-40) immortalized murine
endothelial cells (SVEC) and SVEC-derived stable cell lines
expressing KSHV vGPCR or KSHV vCyclin and vFLIP (EC-
vGPCR, EC-vCYC/vFLIP) were described previously [15]. The
Rapamycin-Resistant mTOR (RR-mTOR) was transfected along
with the pTracer-EF/Bsd plasmid (Invitrogen) into EC-vGPCR or
EC-vCYC/vFLIP. Cells were then stably selected with Blasticidin
(Invitrogen). siRNA delivery into cultured cells was performed
using Hiperfect (Qiagen). For conditioned media preparation,
HMEC1 were transfected with Tet REV TA and pBIG AU5
vGPCR, serum starved and treated with doxycycline (Dox; 1
mg/ml). 24 h later, supernatants from untreated (Control CM) and
Dox treated (vGPCR CM) cells were collected, centrifuged at
1000 g for 10 min, and concentrated 10 times with centrifugal
filters (Millipore).
Reverse transcriptase PCR
Total RNA was isolated using the GenElute Mammalian Total
RNA Miniprep kit (Sigma-Aldrich) according to manufacturer’s
protocol and reverse transcription was performed using Super-
Script III First-Strand Synthesis System (Invitrogen). Upon
extraction of mRNA, cDNA was obtained using the SuperScript
III First-Strand Synthesis System from Invitrogen. Subsequently,
the PCR reaction was carried out using the Mastercycler
thermocycler from eppendorfs (2 min at 94uC; 30 cycles of 94uC
for 30 seconds, 50uC for 30 seconds, 72uC for 1 minute; and
5 minutes at 72uC). Primers for human VEGF were: 59-GG-
GCAGAATCATCACGAAGT-39 (sense) and 59-TGGTGAT-
GTTGGACTCCTCA-39 (anti-sense). Primers for human HIF-
1a were: 59-GCAAGCCCTGAAAGCGCAAG-39 (sense) and 59-
GTGAGGCTGTCCGACTTTGA-39 (anti-sense). For HIF-2a,
primers employed were: 59-GTCTCTCCACCCCATGTCTC-39
(sense) and 59-GGTTCTTCATCCGTTTCCAC-39 (anti-sense).
Amplification of GAPDH sequence was used for normalization.
Western blots and Immunohistochemistry
Western blots and immunohistochemistry were performed as
previously described [12]. Antibodies recognizing AU1, AU5 and
HA epitopes were purchased from Covance. Antibodies against
the following proteins were employed: S6K, p-S6K (T389), S6,
p-S6 (S240/244), AKT, TSC2, p-TSC2 (T1462), ERK1/2,
IKKb, p-IKK-a/b (S180/181), mTOR, p-mTOR (S2448), p38,
p-p38 (T180/Y182), HIF-1a and HIF-1b from Cell Signaling;
HIF-2a and P-TSC2 (S664) (immunohistochemistry) from Novus
Biologicals; TSC1 from Invitrogen; p-TSC1 (S511) from Bethyl
Laboratories; LANA-1 from Leica Microsystems; p-AKT (S473)
from R&D Systems; p-ERK1/2 (T202/Y204) from BD Biosci-
ences; and Actin from Santa Cruz. For p-TSC2 (S1254),
antibodies from Enogene and Cell Signaling were used for
Western blot and immunohistochemistry, respectively. For VEGF,
antibodies from R&D Systems and Abcam were used for Western
blot and immunohistochemistry, respectively. The antibody
recognizing vGPCR was kindly provided by Dr. Gary S. Hayward
(Johns Hopkins University, Baltimore, MD).
Tumorigenesis assays
All procedures involving animals were approved by the
Institutional Animal Care and Use Committee. Murine vGPCR
tumors were obtained as described in ref 12. Briefly, TIE2-tva
transgenic mice expressing in vascular endothelium the avian
leukosis virus (ALV) receptor, TVA, were injected i.p. with ALV-
derived retrovirus encoding for KSHV vGPCR. Macroscopic
vGPCR tumors developed in 4 months predominantly in ear, tail,
paw and GI tract. For tumor allograft formation, cells expressing
vGPCR (EC-vGPCR or EC-vGPCR/RR-mTOR) were mixed
with cells expressing vCyclin and vFLIP (EC-vCYC/vFLIP or EC-
vCYC/vFLIP/RR-mTOR), in a (1:10) ratio (10
5:10
6 cells). These
mixed cell populations were then injected into the right flank of 8-
wk-old athymic (nu/nu) nude female mice as previously described
[15]. For these in vivo studies, Digoxin stock solution (Sigma-
Aldrich) was dissolved in DMSO and Rapamycin (LC Laborato-
ries) was dissolved as previously described [19]. Drug treatment
was initiated when estimated tumor weight reached around 150–
200 mg. For this procedure, tumor-bearing animals were
randomly grouped (control, n=5; drug-treated group, n=5) and
treated with Rapamycin (10 mg/kg) or Digoxin (2 mg/kg) or an
equal volume of vehicle. For Rapamycin, treatment schedule was
a single injection per animal given i.p. for 5 consecutive days [19].
For Digoxin, treatment schedule was a single injection per animal
given i.p. for 10 consecutive days [31]. The animals were
monitored twice weekly for tumor formation. The longest length
(L) and shortest width (W) of the tumor were measured using a
caliper at different time points throughout the experiment. Tumor
volume was then converted into tumor weight using the formula
LW
2/2, as described previously [19]. Results of animal experi-
ments were expressed as mean estimated tumor weight 6 SD.
When appropriate, animals were euthanized, and tissue was fixed
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analysis.
Human tissues
Four patients diagnosed with KS (multiple lesions) at University
of Maryland Dental School or School of Medicine, between 1990
and 2010, were identified. Formalin-fixed paraffin-embedded
tissue samples were obtained from the pathology archives for
immunohistochemical studies. Representative hematoxylin and
eosin sections of each tumor were reviewed and the diagnosis was
confirmed by immunohistochemistry using a specific antibody
recognizing KSHV Latency-associated Nuclear Antigen-1
(LANA-1). The Institutional Review Board (IRB) protocol was
exempt.
Statistical Analysis
In all cases, results are shown as a mean value 6 SD from at
least three independent experiments. Western blot scans are
representative of at least three independent experiments. Statistical
analysis was performed with Prism 4.2 software (GraphPad).
ANOVA test: ***, p,0.001; **, p,0.01; *, p,0.05.
Supporting Information
Figure S1 Specific vGPCR factors induce TSC2/1
phosphorylation at different sites. (A) Phosphorylation of
S6K and S6 upon treatment of HMEC1 with different vGPCR
(recombinant) proteins: IL-8, GROa, VEGF, PDGF, IL-1b, IL-
10, IL-6, TNFa, IP-10, or SDF1a. Cells were pretreated with
(50 nM) Rapamycin, where corresponding. (B) Phosphorylation of
TSC2/1 (TSC2
T1462, TSC2
S664, TSC2
S1254 and TSC1
S511)o r
S6K upon treatment of HMEC1 with different recombinant
cytokines, chemokines, and growth factors, as described in (A). (C)
Analysis of the levels of phosphorylation of TSC2/1 (TSC2
T1462,
TSC2
S664, TSC2
S1254 and TSC1
S511) shown in (B).
(TIFF)
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